Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
15.14
+0.04 (0.26%)
At close: Feb 13, 2026, 4:00 PM EST
15.16
+0.02 (0.13%)
After-hours: Feb 13, 2026, 7:27 PM EST
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $3.29M in the quarter ending September 30, 2025, with 16.58% growth. This brings the company's revenue in the last twelve months to $10.30M, down -8.79% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$10.30M
Revenue Growth
-8.79%
P/S Ratio
8.99
Revenue / Employee
$127,148
Employees
81
Market Cap
193.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 155.10M |
| Arcturus Therapeutics Holdings | 97.60M |
| Alector | 69.05M |
| Voyager Therapeutics | 31.32M |
| Silence Therapeutics | 25.83M |
| Sol-Gel Technologies | 18.97M |
| Ovid Therapeutics | 6.61M |
| Humacyte | 1.57M |
TNXP News
- 15 days ago - Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - GlobeNewsWire
- 6 weeks ago - Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewsWire
- 6 weeks ago - Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - GlobeNewsWire
- 2 months ago - Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications - Seeking Alpha
- 2 months ago - Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - GlobeNewsWire